Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm

NCT06006403 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Relapse Leukemia
Refractory Leukemia

Interventions

BIOLOGICAL: CD123 targeted CAR-NK cells

Sponsor

Chongqing Precision Biotech Co., Ltd

Collaborators

[object Object]